Venetoclax Registry

Sponsor
Hannover Medical School
Study ID
NCT03662724
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.

Study Details

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax

Key Dates

Start date
Nov 1, 2017
Status verified
Feb 2021
Primary completion
Nov 1, 2021
Completion
Nov 1, 2025

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Overall response rate of Venetoclax treatment. [ Time Frame: 4 months ]

Central Contacts

Related Studies